These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 36880362)

  • 1. Initial outcomes of a dedicated multidisciplinary non-alcoholic fatty liver disease clinic: a retrospective cohort study.
    Commins I; Clayton-Chubb D; Melton S; Majeed A; Kemp W; Roberts SK
    Intern Med J; 2023 Nov; 53(11):2065-2072. PubMed ID: 36880362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. When the liver gets stiff, the tough get moving.
    Nguyen TH; Wardell R; Chitturi S; Teoh N; Farrell G
    J Gastroenterol Hepatol; 2020 Jun; 35(6):953-959. PubMed ID: 31867782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bariatric Surgery as an Efficient Treatment for Non-Alcoholic Fatty Liver Disease in a Prospective Study with 1-Year Follow-up : BariScan Study.
    Nickel F; Tapking C; Benner L; Sollors J; Billeter AT; Kenngott HG; Bokhary L; Schmid M; von Frankenberg M; Fischer L; Mueller S; Müller-Stich BP
    Obes Surg; 2018 May; 28(5):1342-1350. PubMed ID: 29119336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.
    Katsagoni CN; Papatheodoridis GV; Ioannidou P; Deutsch M; Alexopoulou A; Papadopoulos N; Papageorgiou MV; Fragopoulou E; Kontogianni MD
    Br J Nutr; 2018 Jul; 120(2):164-175. PubMed ID: 29947322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
    Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease.
    Loong TC; Wei JL; Leung JC; Wong GL; Shu SS; Chim AM; Chan AW; Choi PC; Tse YK; Chan HL; Wong VW
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1363-1369. PubMed ID: 27936280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic fatty liver disease patients attending two metropolitan hospitals in Melbourne, Australia: high risk status and low prevalence.
    George ES; Roberts SK; Nicoll AJ; Reddy A; Paris T; Itsiopoulos C; Tierney AC
    Intern Med J; 2018 Nov; 48(11):1369-1376. PubMed ID: 29845719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of a dedicated care pathway for nonalcoholic fatty liver disease in an integrated US healthcare system demonstrates support of weight management and improved ALT.
    Patton H; Burchette R; Tovar S; Pio J; Shi J; Nyberg LM
    BMC Gastroenterol; 2020 Oct; 20(1):362. PubMed ID: 33129272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China.
    Yu XY; Song XX; Tong YL; Wu LY; Song ZY
    Medicine (Baltimore); 2020 Nov; 99(48):e23360. PubMed ID: 33235107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy.
    Cassinotto C; Boursier J; de Lédinghen V; Lebigot J; Lapuyade B; Cales P; Hiriart JB; Michalak S; Bail BL; Cartier V; Mouries A; Oberti F; Fouchard-Hubert I; Vergniol J; Aubé C
    Hepatology; 2016 Jun; 63(6):1817-27. PubMed ID: 26659452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
    Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
    Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease.
    Shima T; Sakai K; Oya H; Katayama T; Mitsumoto Y; Mizuno M; Kanbara Y; Okanoue T
    J Gastroenterol; 2020 Jan; 55(1):100-112. PubMed ID: 31538241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care.
    Hofmann WP; Buggisch P; Schubert L; Dikopoulos N; Schwenzer J; Muche M; Felten G; Heyne R; Ingiliz P; Schmidt A; Stein K; Wedemeyer H; Berg T; Wiegand J; Lammert F; Zeuzem S; Schattenberg JM
    JHEP Rep; 2020 Dec; 2(6):100168. PubMed ID: 32964201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.
    Petta S; Di Marco V; Pipitone RM; Grimaudo S; Buscemi C; Craxì A; Buscemi S
    Liver Int; 2018 Nov; 38(11):2060-2068. PubMed ID: 29577560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD.
    Gidener T; Dierkhising RA; Mara KC; Therneau TM; Venkatesh SK; Ehman RL; Yin M; Allen AM
    Hepatology; 2023 Jan; 77(1):268-274. PubMed ID: 35642504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD.
    Sun DQ; Ye FZ; Kani HT; Yang JR; Zheng KI; Zhang HY; Targher G; Byrne CD; Chen YP; Yuan WJ; Yilmaz Y; Zheng MH
    Diabetes Metab; 2020 Sep; 46(4):288-295. PubMed ID: 31786360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD.
    Pennisi G; Enea M; Pandolfo A; Celsa C; Antonucci M; Ciccioli C; Infantino G; La Mantia C; Parisi S; Tulone A; Di Marco V; Craxì A; Cammà C; Petta S
    Clin Gastroenterol Hepatol; 2023 May; 21(5):1293-1302.e5. PubMed ID: 35842119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver stiffness measurement in non-alcoholic fatty liver disease: Two is better than one.
    Chuah KH; Lai LL; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2020 Aug; 35(8):1404-1411. PubMed ID: 31907981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient elastography in healthy subjects and factors influencing liver stiffness in non-alcoholic fatty liver disease: An Italian community-based population study.
    Conti F; Vukotic R; Foschi FG; Domenicali M; Giacomoni P; Savini S; Lanzi A; Dall'Aglio AC; Saini G; Matroroberto M; Bernardi M; Stefanini GF; Andreone P
    Dig Liver Dis; 2016 Nov; 48(11):1357-1363. PubMed ID: 27522549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.